Introduction
Cancer is a heterogeneous disease with intra-and inter-tumor genomic diversity that determines cancer initiation, progression and treatment. The understandings of cancer biology and the development of therapeutics have been aided greatly by a variety of mouse tumor models, including cell line-derived xenografts (CDXs), patient derived-xenografts (PDXs), genetically engineered mouse models (GEMMs), cell line-or primary tumor-derived homografts in syngeneic mice and so on (reviewed by (Day, Merlino, & Van Dyke, 2015; Khaled & Liu, 2014; Li, Feuer, Ouyang, & An, 2017; Walrath, Hawes, Van Dyke, & Reilly, 2010) ). These models differ in their generation, host and tumor genomics and biology, availability, and research utilizations. For example, immunotherapies are tested in immunocompetent models such as GEMMs and syngeneic models.
Past decades witnessed the accelerated creation, distribution, profiling and characterization of mouse tumor models (Byrne et al., 2017; Gao et al., 2015; Guo et al., 2016; Krupke et al., 2017; Stewart et al., 2017; Townsend et al., 2016) . The abundant collections made it possible to conduct the so-called "mouse clinical trials (MCTs)", in which a panel of mouse models, dozens to hundreds, are used to evaluate therapeutic efficacy, discover/validate biomarkers, study tumor biology and so on. MCTs demonstrated faithful clinical predictions in multiple studies (Bardelli et al., 2013; Bertotti et al., 2011; Bertotti et al., 2015; Gao et al., 2015; Migliardi et al., 2012; Yao et al., 2017) .
While most reported MCTs used PDXs, MCTs using other mouse models, such as syngeneic models, are now widely performed as well.
Because of their resemblance to clinical trials, MCTs are often analyzed by methods for clinical trials. For example, overall survival (OS) and progression-free survival (PFS) are estimated by tumor volume increase, Cox proportional hazards models are used for survival analysis, response categories are defined by tumor volume change and objective response rate (ORR) is calculated (Bertotti et al., 2015; Gao et al., 2015; Houghton et al., 2007) . However, MCTs differ from clinical trials in many ways: (1) a mouse model have mice in all arms, one is usually a vehicle arm; (2) there can be more than one mouse for each mouse model in each arm; (3) tumor volumes are routinely measured; (4) mouse models are usually characterized with genomic/pharmacology/histopathology annotations; (5) MCTs are done in labs that reduces/removes various noise and inconvenience encountered in clinical trials, such as dropouts, long trial time and concomitant medication.
In this study, we combine empirical data analysis, statistical modeling and computational simulations to address some key issues for MCTs, including the determination of animal numbers (number of mouse models and number of mice per mouse model), statistical power calculation, quantification of efficacy difference between mice/mouse models/drugs, survival analysis, biomarker discovery/validation with and beyond simple efficacy readouts, handling of mouse dropouts, missing data and difference in tumor growth rates, study of mechanisms of action (MoA) for drugs. We will also show MCTs can explain discrepant clinical trial results.
RESULTS

Determining number of mice for categorical responses
We collected tumor volume data under drug treatment for 26127 mice from 2883 unique treatment PDXs, 11139 mice from 1219 unique treatment CDXs, and 5945 mice from 637 unique treatment syngeneic models. A unique treatment model is a mouse model treated by a drug in a study. Every unique treatment has at least 8 mice. Categorical drug response was determined by 4 methods (see Materials and Methods), and we illustrate the results using the mRECIST criteria, which classifies drug response into 4 categories: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). For each unique treatment model, its response is the majority response of all mice. We observed that individual mouse responses matched the majority response most often for PD: 90% for PDXs, 95% for CDXs and syngeneic models (Fig. 1a-c) . The other 3 response categories exhibit lower concordance, particularly so for syngeneic models. Of the 10 unique treatment syngeneic models classified as CR, only half of the mice had complete response as well, while 17% of mice were PD and resistant to treatment. Such polarized response pattern is observed in the other 3 methods, too (Fig. S1-S3 ). Large variance exists for all 4 response categories. For example, only about 70% of individual responses matched the majority response for a third of the 107 unique treatment PDX models categorized as CR, although the average is 83%.
Measurement accuracy increases with number of mice. We randomly sampled n (n=1, 3, 5, 7) mice from all the mice in a treatment and obtained a majority response, which was then compared with the actual majority response. The procedure was repeated for 1,000 times to generate statistical results ( Fig. 1d-f ). Accuracy increases with mouse number for all 4 categories, and their unweighted average is highest in CDXs, which is slightly higher than PDXs, while syngeneic models have much lower accuracy (Fig. 1g) . Therefore, more mice are needed for syngeneic models to achieve similar accuracy as PDXs/CDXs. For example, accuracy is comparable between syngeneic studies with 5 mice per model and PDX/CDX studies with 1 mouse per model. Similar patterns are also seen in the other 3 methods (Fig. S1-S3 ).
All the 4 methods categorize responses based on relative tumor volume (RTV) at a later day to treatment initiation day, but differ in specific thresholds. As such, a unique treatment model can be categorized differently. We found that there is a good overlapping for unique treatment models classified as objective response between the 4 methods ( Fig. 1h-j) , and their objective response rates (ORR) are similar. (Table S1 ). Nevertheless, there are many models only unique to some methods as OR, cautioning method-specific bias and applicability. For example, the mRECIST considers averaging tumor reduction for a period of time, therefore, a unique treatment model can be classified as PD even though tumor completely disappears at end of study (Fig. S4) .
Determining number of mice for continuous responses
Drug efficacy can be measured by continuous responses, some are direct adaption of clinical endpoints (e.g., PFS and OS), others are unique to mouse studies that use data from both vehicle and drug treatment groups (e.g., RTV ratio between drug and vehicle groups). We calculated the estimation errors of PFS and RTV ratio computed from n (n=1 to 9) mice randomly sampled from the 10 mice in a study, and obtained the quantitative relationship between estimation errors and mouse numbers (Fig. 2) . Large estimation errors are inherent to small sample sizes, particularly so for syngeneic models. For example, percent error of PFS is greater than 20% for 63% syngeneic mice and for about half of PDX/CDX mice (Fig. 2d) . Estimation errors are reduced sharply by addition of more mice when n is small. For RTV ratio, 3 mice in both drug and vehicle group already lift mice with absolute error <0.2 from 60% to above 80% for PDXs/CDXs (Fig. 2h) .
Similar results hold for other continuous endpoints as well (Fig. S5) .
Modeling MCTs as clustered longitudinal studies
It is convenient to measure drug efficacy by a categorical or continuous endpoint, but those approaches also suffer from loss of information and other drawbacks. For example, it is somewhat arbitrary to choose a day to calculate RTV ratio and TGI; it adds logistic burden to match mice with comparable tumor volume at treatment initiation day (Laajala et al., 2016) ; it is difficult to deal with mouse dropouts. These shortcomings can be overcome by modeling MCTs as clustered longitudinal studies, in which a cluster is consisted of all mice of a mouse model so they share genomic profile and have more similar drug response. Each mouse is in a longitudinal study. It can be shown that tumor growth in majority of mice follows exponential kinetics (Fig. S6) . Therefore, we can model the clustered longitudinal studies by a 3-level linear mixed model (LMM) on the logtransformed tumor volumes (logTV) and day (Fig. 3a) . There are covariates associated with mouse models such as cancer type and genomic features, which can be used for examining efficacy difference on cancers and for discovering predictive biomarkers.
We use one example to demonstrate the modeling of MCTs by LMMs for efficacy evaluation and comparison. In this MCT, cisplatin-a chemotherapy drug-was administrated to 42 PDXs (4mg/kg, weekly dosing for 3 weeks), including 13 esophageal cancers (ES), 21 gastric cancers (GA) and 8 lung cancers (LU), each PDX with 5 to 9 mice (Fig. S7) . We fit the efficacy data by a LMM (Equation 3 in Materials and Methods), which explicitly models tumor growth rate heterogeneity and drug response heterogeneity at both PDX level and mouse level. Model fitting is satisfactorily ( Fig. S8, Table 1 ). We conclude that (1) under vehicle treatment, tumor in GA grows slightly faster than ES, while tumor growth is much faster in LU; (2) cisplatin has comparable efficacy on the 3 cancers (p-values for 5 and 6 are >0.05). The results can be readily visualized from the mean growth curves for the 3 cancers under (Fig. 3b) .
Statistical power and sample size determination in MCTs
Much like clinical trials, rational design of MCTs requires statistical power calculation and sample size determination-number of mouse models and number of mice per mouse model. We demonstrate this under the LMM framework with the following assumptions (1) a balanced n:n design in which there are n (≥1) mice in both drug and vehicle groups, and (2) a 21-day trial with tumor volume measured at treatment initiation and then twice every week to produce 8 data points for every mouse. Drug efficacy is measured by how much drug treatment slows down tumor growth (β2/β1 in Equation 4). Power curves were obtained by computational simulations based on parameters obtained from fitting the cisplatin dataset by Equation 4 (Fig. 3c) .
We observed that if the number of PDXs is the same, more mice per PDX confer better statistical power. For example, to achieve 80% power, we need about 28 PDXs for the 1:1 design, and 11 PDXs for the 3:3 design. More importantly, statistical power is comparable for designs with similar number of total mice. For example, when the drug efficacy is 20%, that is, the drug reduces tumor growth rate by 20%, the following designs all achieve 90% power at 0.05 significance level: 36 PDX with 1:1 design, 19 PDXs with 2:2 design, 13 PDXs with 3:3 design, 10 PDXs with 4:4 design, and so on. Therefore, in practice, we can use the 1:1 design if there are many PDXs at disposalthe 1x1x1 approach (Gao et al., 2015) . Alternatively, we can increase the number of mice per PDX to boost power, especially when there is only a limited number of suitable PDXs, e.g., PDXs carrying a particular mutation or PDXs of a specific subtype.
We also observed that fewer PDXs are needed for a more potent drug to reach same statistical power. For example, to achieve 80% statistical power at 0.05 significance level by the 3:3 design, we need about 40, 11, and 5 PDXs for drugs with 10%, 20%, and 30% efficacy, respectively. When a drug is potent enough, all n:n designs achieve high power with very small number of PDXs. In such cases, we use a good number of PDXs not for statistical power but for better representation of tumor heterogeneity.
Survival analysis in MCTs
In clinical trials, patient survival is usually assumed to be independent of each other. In MCTs, this assumption no longer holds because mice are now clustered within PDXs, and mice of same PDX tend to have more similar survival time, while their survival time between treatments is highly correlated (Fig. 4a) . Further, PDXs can vary greatly in growth rate (or hazard) and drug response (Fig. S9) (Fig. 4c) . These results show that without considering PDX heterogeneity, drug effect can be severely misestimated.
We performed statistical power analysis for the survival analysis by assuming the n:n designs and using parameters estimated from the cisplatin MCT with Weibull hazard functions (Figure 4d ).
Like in LMMs, statistical power is similar for designs with similar total number of mice.
Biomarker discovery in MCTs
Genomic correlation to cetuximab efficacy in solid tumors has been well documented (Bertotti et al., 2015) , and we previously reported a MCT for a cohort of 20 gastric cancer PDXs and found that EGFR expression to be a predictive biomarker for cetuximab on gastric cancer (L. Zhang et al., 2013) . The cohort is now expanded to 27 PDXs (Fig. S10) . We observed a strong correlation between EGFR expression and drug efficacy measured by tumor growth inhibition or TGI (Fig.   5a ). But EGFR is ranked 157 th out of all genes.
We used a LMM that explicitly models a gene's effect on tumor growth to fit the efficacy data (Equation 6 in Materials and Methods). EGFR stands out as the most significant gene and its pvalue, being1.510 -23 , is at least five orders of magnitude smaller than all other genes (Fig. 5b) .
EGFR as a predictive biomarker for cetuximab on gastric cancer is supported by a phase 2 clinical trial (X. Zhang et al., 2014 ) and a phase 3 clinical trial with data re-interpretation ( Fig. S11 ) (Lordick et al., 2013) . This study shows that simple analysis can produce many false positive hits to hamper biomarker discovery, especially when a drug target is unknown or there are off-target effects, while the more sophisticated LMM method can be superior in biomarker discovery.
Mechanism of action study in MCTs
Investigating the relationship between efficacy and genomic data facilitates the study of a drug's mechanism of action (MoA). Like in biomarker discovery, simple categorical and continuous endpoints, as a gross summery of efficacy, have various drawbacks. For example, the 4 categorical methods only measure efficacy in drug treatment group, ignoring the relative drug-to-vehicle efficacy. RTV ratio and TGI are dependent on calculation day and tumor growth rate (Fig. S12) .
Irinotecan is a DNA topoisomerase I inhibitor that interrupts cell cycle in the S-phase by irreversibly arresting the replication fork, therefore causing cell death (Xu & Villalona-Calero, 2002 ). We conducted a MCT for 16 PDXs (Fig. S13) , each PDX with 3 to 10 mice. We modeled the effect of gene expression on drug efficacy by a LMM (Equation 6). Top ranked genes were highly enriched for the cell cycle pathway R-HSA-160170 in the Reactome 2016 database (Fig.   5c ), and for DNA replication initiation (Gene Ontology annotation GO: 0006270) (Fig. 5d) , which perfectly reveals the MoA for irinotecan. A highly connected protein-protein interaction network for cell cycle is also identified from the 100 top ranked genes (Fig. 5e) . In contrast, endpoint based methods are far less insightful (Table S2-S4, Fig. 5c-d) .
MCTs can explain paradoxical clinical trial results
Conflicting clinical trial reports exist regarding the role of ERCC1 expression in predicting cisplatin treatment on gastric cancer: some claimed that patients benefit more from low ERCC1 expression (De Dosso et al., 2013; Hirakawa et al., 2013; Kwon et al., 2007; Metzger et al., 1998; Miura et al., 2015) , some stated the opposite (Baek et al., 2006; Bamias et al., 2010; Kim et al., 2011) , while still others found no connection at all (Sonnenblick et al., 2012) .
In a previous section, we described a cisplatin MCT which included 21 gastric cancer PDXs. We fit the tumor volume data by Equation 6. Parameter 2 quantifies how ERCC1 expression affects tumor growth when there is no drug intervention, as seen from the vehicle growth curves (Fig. 5f ).
Parameter 4 evaluates how ERCC1 expression impacts cisplatin's efficacy on tumor growth, as seen by comparing the cisplatin growth curves with corresponding vehicle growth curves. These two parameters are at comparable magnitude but with opposite signs ( 2 = -0.0155 and 4 = 0.0136). Therefore, when ERCC1 expression gets higher, tumor grows slower, but the benefit of cisplatin treatment is smaller as well (Fig. 5f) .
In a clinical trial, patients with low/negative ERCC1 expression would have worse prognosis if they were not treated, and they could benefit more from cisplatin treatment. With treatment, their prognosis is improved, but whether it is better than the prognosis of ERCC1 high/positive patients is undetermined and depends on the trial population, hence we saw conflicting study conclusions.
Discussion
MCTs are population-based efficacy trials mimicking human trials. Multiple mice are usually used per mouse model per arm to improve accuracy of efficacy measurement. For example, Bertotti et al. used 6 mice per PDX per arm in a two-arm MCT with 85 colorectal cancer PDXs to identify HER2 as a therapeutic target in Cetuximab-resistant colorectal cancers (Bertotti et al., 2011) . It may also be feasible to use one mouse per model per arm when there is a large number of mouse models, which compensate the loss of measurement accuracy on individual mice (Gao et al., 2015; Murphy et al., 2016; Townsend et al., 2016; Williams, 2018) . Caution must be exercised to use this approach though, when the number of mouse models is small, or high measurement accuracy of individual mouse models is mandated, or response varies greatly among mice of same mouse models, as commonly observed for immunotherapeutic agents on syngeneic models.
Our study established theoretic foundations for the design and analysis of MCTs. We first investigated tumor growth kinetics. Many complex mathematical models were used to describe tumor growth (Benzekry et al., 2014 ), but might not be particularly advantageous at the expense of more parameters and the need of more data points for model fitting. The exponential growth model is simple, interpretable and linear after a logarithmic transformation, and was shown to be adequate in most cases. Consequently, LMMs can describe nearly all MCTs, using quadratic terms of time if necessary.
We introduced additive frailty models to perform survival analysis for MCTs. The definition of PFS/OS can vary. For example, OS can be defined same as in human trials for leukemia PDXs (Townsend et al., 2016) . For both LMMs and frailty models, we performed power simulations that give concrete recommendations on trial design. In particular, we answered the frequently asked questions on how many mouse models and how many mice per model to use, with flexible combination of the two numbers. MCTs can be asymmetric, i.e., unequal numbers of mice in arms. LMMs and frailty models are flexible for covariates, for example, a fixed effect for site can be incorporated if a MCT is conducted at multiple sites.
In conclusion, methods proposed in this study make the design and analysis of MCTs more rational and powerful.
Materials and Methods
Mouse models, studies and transcriptomic profiling
The establishment of mouse models and the conduct of mouse efficacy studies were described previously (Yang et al., 2013; Yang et al., 2016; L. Zhang et al., 2013) . Briefly, for PDX models, freshly resected patient tumors were sliced into roughly 3×3×3mm 3 chunks and engrafted subcutaneously on the flanks of immunocompromised mice (BALC/c, NOD/SCID, NOG, etc.). platforms by certified service providers, as previously described (Guo et al., 2016) .
Categorical efficacy endpoints in mouse studies
Four categorical endpoint methods were evaluated, including the Response Evaluation Criteria In Solid Tumors (RECIST) criteria (Eisenhauer et al., 2009 ), a 3-category or 3-cat method (Bertotti et al., 2015) , the 4-response mRECIST criterion (Gao et al., 2015) , and a 5-category or 5-cat method (Houghton et al., 2007) . Briefly, the RECIST-based criterion categorizes drug responses into complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) based on relative tumor volume, or RTV, at a later day relative to treatment initiation day (CR: Objective response is defined as OR, CR+PR, MCR+CR+PR in the 3-cat, RECIST/mRECIST and 5-cat methods, respectively.
Continuous efficacy endpoints in mouse studies
We briefly describe 4 continuous endpoints here. (a) Progression-free survival (PFS) is defined as tumor volume doubling time and obtained by linear intrapolation on tumor growth data.
Specifically, if the PFS is between day d1 and day d2, then it is 1 + ( 2 − 1 )(2 0 − 1 )/( 2 − 1 ) where TV1, TV2 and TV0 are tumor volumes at d1, d2 and treatment initiation day.
(b) RTV ratio is the ratio of RTV between drug group and vehicle group at a specific day d and equals RTVt /RTVc, where RTVt is the relative tumor volume between day d and treatment initiation day for the drug treatment group, and RTVc is accordingly defined for the vehicle group.
(c) Tumor growth inhibition (TGI) has several definitions, it can be defined as 1-RTVt /RTVc, or as 1-T/C where T and C are tumor volume changes relative to initial volume for drug group and vehicle group, respectively, at a specific day. (d) The ratio of growth rates between drug group and vehicle group is defined as kt /kc where kt and kc are the growth rates obtained by modeling tumor growth data for the two groups by Equation 1. More general, we can introduce a new endpoint called AUC ratio, which reduces to ratio of growth rates when tumor grows under exponential kinetics (Fig. S5) . Unique treatment models with at least 10 mice were used to calculate continuous endpoints, including 621 unique treated PDXs, 739 CDXs and 438 syngeneic models.
Modeling tumor growth
Tumor growth under exponential kinetics is modeled by
Where TV0 is the initial tumor volume, TVd is the tumor volume at day d, and k is the tumor growth rate. A logarithmic transformation gives
Linear mixed models for the cisplatin dataset
A general model can be specified for tumor volume, in log scale, at day t for mouse i within PDX j as follows:
LU is lung cancer, GA is gastric cancer and ES is esophageal cancer. The model uses vehicle in ES as the reference. There are 6 fixed effects: 0 for the intercept, 1 for the time slope, 2 and 3 quantify the growth rate difference of GA and LU with respect to ES, 4 measures cisplatin effect, 5 and 6 measures if GA and LU respond differently to cisplatin. The model also has 5 random effects, including the residual . In a MCT, we view the cohort of PDXs as random samples from a PDX or patient population, therefore, they have different growth rates, which is modeled by random effect 1 associated with the time slope. Similarly, we model growth difference for mice within a PDX by the random effect 1 | . Mice and PDX may have different starting tumor volumes, modeled by the two random effects on intercept 0 and 0 | .
Power calculation based on computational simulation
Power calculation was based on parameters (e.g., variance and covariance of random effects) estimated from fitting the cisplatin dataset by a LMM:
At significance level =0.05, we obtained power curves by simulations for β2/β1= -0.1 to -0.9, that is, drug treatment reduces tumor growth rate by 10% to 90%.
Additive frailty models for survival analysis
In the additive frailty model, the hazard function for the j-th mouse of the i-th mouse model is given
where ℎ assuming Weibull distribution for the hazard function (Rondeau & Gonzalez, 2005) .
Linear mixed models for the biomarker discovery
The following LMM is used for single-gene biomarker discovery by fitting efficacy data from a MCT:
In this model, Gene is a covariate for the genomic status (expression, mutation, copy number variation, etc.) of a gene.
Gene list enrichment analysis
A list of top ranked genes were used as input to the Enrichr web server (http://amp.pharm.mssm.edu/Enrichr/) for their enrichment in the "Reactome 2016" pathway database and in the "GO Biological Process 2018" database (Chen et al., 2013) . Adjusted p-values were used to rank enriched pathways and biological processes.
Protein-protein interaction network analysis
A list of top ranked genes were analyzed for protein-protein interactions in the STRING database (version 10.5 at https://string-db.org) (Szklarczyk et al., 2015) . Default settings were used except the value for "minimum required interaction score" changed from "medium confidence (0.400)" to "high confidence (0.700)". RTV ratio between drug and vehicle groups, calculated from n mice (n=1 to 9) randomly sample from a study with at least 10 mice in both drug and vehicle groups, shows deviation to the RTV ratio calculated from all mice in both groups in PDX (e), CDX (f), and syngeneic models (g), x axis is the absolute error, and y axis is the empirical cumulative density function (ECDF) estimated from the random samplings for each n. Absolute error of RTV ratio decreases with increased number of mice, and the error is larger for syngeneic models than 
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